SCHEMBL3353282

SCHEMBL3353282

NC(=O)CC(C(N)=O)c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.63
CYP2C19 P33261 4/20 0.51
SMN1; SMN2 Q16637 2/20 0.48
NPSR1 Q6W5P4 2/20 0.48
CYP2D6 P10635 2/20 0.48
CYP1A2 P05177 1/20 0.48
PKM P14618 1/20 0.48
SLC6A3 Q01959 3/20 0.47
LMNA P02545 3/20 0.47
DRD3 P35462 2/20 0.47
ADORA3 P0DMS8 1/20 0.47
EDNRB P24530 1/20 0.47
MAPK1 P28482 1/20 0.47
MC4R P32245 1/20 0.47
MC3R P41968 1/20 0.47
DRD2 P14416 1/20 0.47
GABBR2 O75899 1/20 0.46
GABBR1 Q9UBS5 1/20 0.46
ALDH1A1 P00352 2/20 0.44
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3353959 0.98 EPHX1 (0.61) EPHX1CYP2C19SMN1; SMN2NPSR1CYP2D6
SCHEMBL2587234 0.88 EPHX1 (0.63) EPHX1CYP2C19SMN1; SMN2NPSR1CYP2D6
SCHEMBL1520271 0.88 GAA (0.54) EPHX1CYP2C19SMN1; SMN2NPSR1CYP2D6
SCHEMBL13544797 0.84 EPHX1 (0.50) EPHX1CYP2C19SMN1; SMN2NPSR1CYP2D6
SCHEMBL12718845 0.84 EPHX1 (0.59) EPHX1CYP2C19SMN1; SMN2NPSR1CYP2D6
SCHEMBL19716696 0.84 EPHX1 (0.59) EPHX1CYP2C19SMN1; SMN2NPSR1CYP2D6
SCHEMBL27419698 0.82 EPHX1 (0.49) EPHX1CYP2C19SMN1; SMN2NPSR1CYP2D6
SCHEMBL7038216 0.82 L3MBTL1 (0.52) EPHX1CYP2C19SMN1; SMN2NPSR1CYP2D6
SCHEMBL27911843 0.81 HDAC7 (0.53) EPHX1CYP2C19SMN1; SMN2NPSR1CYP2D6
SCHEMBL3633833 0.81 EPHX1 (0.56) EPHX1SMN1; SMN2SLC6A3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114249783-A Phenyl succinamide glycoside compound and preparation method and application thereof 山东省分析测试中心 2022-03-29 CN claimed
CN-1181048-C Aminobenzophenones as inhibitors of IL-1 beta and TNF_alpha ������˹ҩƷ��˾ 2004-12-22 CN claimed
JP-2004502669-A 2004-01-29 JP claimed
EP-1377589-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-01-07 EP claimed
EP-1353898-A2 COMPOUNDS TO TREAT ALZHEIMER'S DISEASE Elan Pharmaceuticals, Inc. (US) 2003-10-22 EP claimed
CN-1447789-A Compounds for treating alzheimer's disease ELAN PHARM INC (US) 2003-10-08 CN claimed
WO-2002062804-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2002-08-15 WO claimed
WO-2002002512-A2 COMPOUNDS TO TREAT ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2002-01-10 WO claimed
CN-114249783-B Phenyl butanediamide glycoside compound and preparation method and application thereof 北京东方红航天生物技术股份有限公司 2023-09-01 CN disclosed
CN-109641947-B CD229CAR T cells and methods of use thereof 犹他大学研究基金会 2023-04-14 CN disclosed
CN-114249783-A Phenyl succinamide glycoside compound and preparation method and application thereof 山东省分析测试中心 2022-03-29 CN disclosed
CN-114249783-A Phenyl succinamide glycoside compound and preparation method and application thereof 山东省分析测试中心 2022-03-29 CN disclosed
CN-112299938-B Method for preparing amine compound by reducing amide compound 中国科学院兰州化学物理研究所 2021-12-28 CN disclosed
CN-112299938-A Method for preparing amine compound by reducing amide compound 中国科学院兰州化学物理研究所 2021-02-02 CN disclosed
US-7498436-B2 Substituted hydroxyethylamines PHARMACIA & UPJOHN COMPANY LLC (US) 2009-03-03 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed
US-20070213407-A1 Compounds to treat Alzheimer's disease ELAN PHARMACEUTICALS AND PHARMACIA & UPJOHN COMPANY LLC 2007-09-13 US disclosed
US-7214715-B2 Compounds to treat Alzheimer's disease PHARMACIA & UPJOHN (US) 2007-05-08 US disclosed
US-7176242-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-02-13 US disclosed
US-20060106256-A1 Substituted hydroxyethylamines PHARMACIA & UPJOHN COMPANY 2006-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213407-A1 Compounds to treat Alzheimer's disease PSEN2, PSEN1, CHAT EPHX1 239/4885CYP2C19 1374/4885SMN1; SMN2 539/4885
US-20060106256-A1 Substituted hydroxyethylamines HNMT, PNMT, BCHE EPHX1 95/4885CYP2C19 430/4885SMN1; SMN2 457/4885
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP EPHX1 1903/4885CYP2C19 4077/4885SMN1; SMN2 1298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.